Shire, Acceleron to Collaborate on Treatments for Rare Muscle Diseases
Shire Pharmaceuticals has signed a $498 million collaboration agreement with Acceleron Pharma to develop and commercialize treatments for muscular and neuromuscular disorders.
muscular dystrophy